Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Tim Pickles
  • Rieke Alten
  • Maarten Boers
  • Vivian Bykerk
  • Jared Christensen
  • Robin Christensen
  • Hubert van Hoogstraten
  • Lee S Simon
  • Lai-Shan Tam
  • Ernest H Choy
View graph of relations

OBJECTIVE: Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time.

METHODS: A systematic review assessed design of phase II clinical trials in rheumatoid arthritis.

RESULTS: Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint.

CONCLUSION: The next step is to undertake a systematic review of adaptive designs used in early-phase trials in nonrheumatic conditions.

Original languageEnglish
JournalJournal of Rheumatology
Volume46
Issue number10
Pages (from-to)1406-1408
Number of pages3
ISSN0315-162X
DOIs
Publication statusPublished - Oct 2019

ID: 58098123